Nagai Hirokazu, Takamaru Natsumi, Ohe Go, Uchida Daisuke, Tamatani Tetsuya, Fujisawa Kenji, Iwamoto Seiji, Miyamoto Youji
Dept. of Oral Surgery, Subdivision of Molecular Oral Medicine, Division of Integrated Sciences of Translational Research, Institute of Health Biosciences.
Gan To Kagaku Ryoho. 2011 May;38(5):777-81.
The purpose of this study was to evaluate the effectiveness and adverse events of combination chemotherapy with oral S-1 administration following docetaxel (DOC) treatment by superselective intra-arterial infusion as neo-adjuvant chemotherapy (NAC) for patients with oral squamous cell carcinoma. Thirteen patients were enrolled in this study (9 men and 4 women, with a mean age of 61. 0 years). All patients were given S-1 65mg/m(2) per day for 14 days, and DOC 40-50mg/m(2) by intraarterial infusion was administered. The locoregional response evaluated 3 weeks after administration was 100%, including a 69. 2% complete response. According to Oboshi and Shimosato's classification, histological evaluation of surgical specimens revealed that 3 cases were Grade II a, 4 cases Grade II b, 1 case Grade IV a, and 4 cases Grade IV c. The severe side effects were neutropenia and cerebral infarction. The present study suggests that combination chemotherapy with S-1 and DOC by superselective intra-arterial infusion would be an effective and safe regimen in NAC for oral squamous cell carcinomas.
本研究旨在评估多西他赛（DOC）经超选择性动脉内灌注治疗后口服S-1联合化疗作为口腔鳞状细胞癌患者新辅助化疗（NAC）的有效性和不良事件。本研究共纳入13例患者（9例男性，4例女性，平均年龄61.0岁）。所有患者均给予S-1 65mg/m²，每日1次，共14天，并经动脉内灌注给予DOC 40 - 50mg/m²。给药3周后评估的局部区域反应为100%，其中完全缓解率为69.2%。根据Oboshi和Shimosato的分类，手术标本的组织学评估显示，3例为II a级，4例为II b级，1例为IV a级，4例为IV c级。严重副作用为中性粒细胞减少和脑梗死。本研究表明，S-1和DOC经超选择性动脉内灌注联合化疗在口腔鳞状细胞癌的新辅助化疗中是一种有效且安全的方案。
